Confirm delete?

Bertin Bioreagent
logo
All categories
Contact Us
You are here :

TW9

  • Zoom
    TW9
  • TW9
Cat No: 31588
Biochemicals - Small Molecule Inhibitors
Cayman

TW9 is a dual inhibitor of bromodomain 2 (BD2) in bromodomain-containing protein 4 (BRD4) and histone deacetylase 1 (HDAC1; IC50s = 0.074 and 0.29 µM, respectively).{59828} It is selective for BD2 over BD1 in BRD4 (IC50 = 0.72 µM) and for HDAC1 over H...

More

This product can only be bought through Cayman Chemical. Please contact us.

Territorial Availability: Available through Bertin Technologies only in France
Synonyms:
  • (S)-N-(2-aminophenyl)-4-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)benzamide
Correlated keywords:
  • BR HDAC BD TW-9 PaCa2
Product Overview:
TW9 is a dual inhibitor of bromodomain 2 (BD2) in bromodomain-containing protein 4 (BRD4) and histone deacetylase 1 (HDAC1; IC50s = 0.074 and 0.29 µM, respectively).{59828} It is selective for BD2 over BD1 in BRD4 (IC50 = 0.72 µM) and for HDAC1 over HDAC2 (IC50 = 2.5 µM). TW9 (50 nM) induces apoptosis in, and inhibits proliferation of, MIA PaCa-2 pancreatic cancer cells. It induces cell cycle arrest at the G1 phase in HPAC pancreatic cancer cells when used at a concentration of 2 µM. TW9 acts synergistically with gemcitabine (Item No. 9003096) to reduce the viability of HPAC cells.
Size 1 mg
Shipping dry ice
CAS Number 2614417-90-0
Molecular Formula C32H28ClN7O2S
SMILES CC1=C(C)C(C(C2=CC=C(Cl)C=C2)=N[C@H]3CC(NC4=CC=C(C(NC5=C(N)C=CC=C5)=O)C=C4)=O)=C(S1)N6C3=NN=C6C
Molecular Weight 610,1
Formulation A crystalline solid
Purity ≥98%
Custom Code 2934.99
UNSPSC code 12352100

Click here to ask for your quote and get 15% off Cayman's products.

 

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.

Search